SITC 2017 Abstract Titles – Immune Modulation, Cytokines, and Antibodies

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.

#

Title

Authors

Affiliations

Keywords

P306

A Protein Extract from Fermented Wheat Germ Promotes NK Cell-Mediated Lymphoma Eradication in Mouse Xenografts.

Gustavo Barisone1, Yunpeng Ma1, Mastewal Abuhay1, Robert O'Donnell1, Kathleen Lundeberg1, Sonia Gowda1, William Murphy2, Joseph Tuscano1

1University of California Davis, Sacramento, CA, USA 2University of California, Sacramento, CA, USA

Leukemia/Lymphoma | Immune adjuvant | NK/NK T cell

P307

Expression and function of PD-1 and TIM-3 in non-small cell lung cancer (NSCLC)

Jonathan Travers1, Krtisten McEachern1, Srimoyee Ghosh1, Sridhar Ramaswamy1, David Jenkins1

1TESARO Inc., Waltham, MA, USA

Antibody | Checkpoint blockade | Coinhibition | Cytokine | Gene expression | T cell | Tumor infiltrating lymphocytes (TILs)

P308

A PD-1 x CTLA-4 Bispecific DART® Protein with Optimal Dual Checkpoint Blockade and Favorable Tolerability in Non-human Primates

Alexey Berezhnoy1, Kurt Stahl1, Kalpana Shah1, Tim Gaynutdinov1, Gurunadh Chichili1, Daorong Liu1, Rebecca Johnson1, Ross La Motte-Mohs1, Jessica Hill1, Jonathan Li2, Sergey Gorlatov1, Valentina Ciccarone1, Ralf Alderson1, Hua Li1, James Tamura1, Jennifer Brown1, Jon Wigginton1, Ezio Bonvini1, Paul Moore1, Syd Johnson1

1Macrogenics, INC, Rockville, MD, USA 2Macrogenics, INC, South San Fancisco, CA, USA

Checkpoint blockade | Antibody | Immune suppression | T cell

P309

Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors

Cristina Bergamaschi1, Konstantinos Dimas1, Dimitrios Stellas1, Bethany Nagy1, Shawn Jensen2, Bernard Fox2, Barbara Felber1, George Pavlakis1

1National Cancer Institute at Frederick, Frederick, MD, USA 2Earle A Chiles Research Institute, Portland Providence Cancer Center, Portland, OR, USA

Adoptive immunotherapy | Regulatory T cell (Treg) | Tumor microenvironment | Chemokine | Cytokine | Tumor infiltrating lymphocytes (TILs) | T cell

P310

CSF1/CSF1R signaling blockade triggers release of matrix-degrading proteases in mouse models

Stefan Bissinger1, Martina Schmittnaegel2, Ioanna Keklikoglou2, Michele De Palma2, Sabine Hoves1, Carola Ries1

1Roche Innovation Center Munich, 82377 Penzberg, Germany 2The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

Myeloid cells | Inflammation | Tumor microenvironment | Antibody | Monocyte/Macrophage | Biomarkers

P311

Clinical outcomes of PD-1 inhibition by PD-L1 expression level across malignancies in 204 consecutive patients in a real world oncology setting

Kenneth Byrd1, Tristan Hayes1, Mike Martin2, Lee Schwartzberg2, Ari Vanderwalde2

1University of Tennessee Health Sciences Center, Memphis, TN, USA 2West Cancer Center, Germantown, TN, USA

Antibody | Biomarkers | T cell

P312

AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity

Dhan Chand1, David Savitsky1, Ana Gonzalez1, Christopher Clarke1, Andrea Schuster2, Elise E. Drouin1, Jeremy D. Waight1, Cornelia Mundt2, Gerd Ritter1, Taha Merghoub4, David Schaer4, Rikke B Homlgaard4, Roberta Zappasodi4, Marc van Dijk5, Jennifer S. Buell1, Jean-Marie Cuillerot1, Robert Stein1, Nicholas S Wilson1

1Agenus Inc., Lexington, MA, USA 2Former employee of Agenus Switzerland Inc., Basel, Switzerland 4Memorial Sloan Kettering Cancer Center, New York, NY, USA 5Agenus Switzerland Inc., Basel, Switzerland

Tumor infiltrating lymphocytes (TILs) | T cell | Immune suppression | Antibody | Checkpoint blockade | Coinhibition | Tumor microenvironment | Biomarkers | Cytokine | Costimulation

P313

In vivo Effect of Albumin Binding Domains Attached to Immune Modulators

Haomin Huang1, Keneshia Haenssen1, Anil Bhate1, Supriya Sanglikar1, John Baradei1, Shan Liu1, Senthil Kumar1, Zihao Cui1, Richard Hampton1, Robert Kramer1, John Cini1

1Sonnet BioTherapeutics, Cranbury, NJ, USA

Cytokine | Antibody

P314

Glioblastoma stem-like cell targeting antibodies identified using yeast display biopanning

Paul Clark1, Michael Zorniak1, Benjamin Umlauf1, Yongku Cho1, Eric Shusta1, John Kuo1

1University of Wisconsin - Madison, Madison, WI, USA

Biomarkers | Stem cell/cancer-initiating cell | Tumor antigens | Antibody | Solid tumors

P315

A bispecific fusion protein, ACDClx, can selectively activate T cells against glioblastoma cells in vitro

Rebecca Cook1, Sierra Bichler1, Andrew Diamos1, Braeden Schaefer1, Andrew Niemann1, Hugh Mason1, Tsafrir Mor1, Rachael Sirianni2, Joseph Blattman1

1Arizona State University, Tempe, AZ, USA 2Barrow Neurological Institute, Phoenix, AZ, USA

Targeted therapy | Antibody | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P316

Impact of anti- PD1 on TIL phenotype and function

Caitlin Creasy1, Cara Haymaker2, Marie-Andrée Forget2, Gopal Singh2, Coya Tapia2, Jeane Marie Painter2, Funda Meric-Bernstam2, Chantale Bernatchez2, Aung Naing2

1MD Anderson Cancer Center University of Texas Health Graduate School of Biomedical Sciences, Houston, TX, USA 2University of Texas MD Anderson Cancer Center, Houston, TX, USA

Adoptive immunotherapy | Clinical trial | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Solid tumors

P317

In vivo efficacy and mechanism of action of anti-TIGIT monoclonal antibody CASC-674

Peter de Vries1, Robert Rosler1, Janelle Taylor1, Scott Peterson1

1Cascadian Therapeutics, Inc., Seattle, WA, USA

Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Antibody | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Inflammation | Tumor stroma | Monocyte/Macrophage | T cell

P318

Anti-tumor efficacy and enhancement of T cell effector functions by EOS084448, an antagonist anti-TIGIT antibody

Gregory Driessens1, Julia Cuende1, Sofie Denies1, Chaterine Hoofd1, Florence Lambolez1, Shruthi Prassad1, Virginie Rabolli1, Anthony Cooper2, Christophe Quéva1

1iTeos Therapeutics, Gosselies, Belgium 2Adimab, Lebanon, NH, USA

Costimulation | Immune tolerance | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Coinhibition | Antibody | Immune suppression | Tumor infiltrating lymphocytes (TILs) | T cell

P319

Long-term disease-free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-2 (HD IL2)

Joseph Clark1, Brendan Curti2, Elizabeth Davis3, Howard Kaufman4, Asim amin5, Ajjai Alva6, Theodore Logan7, Ralph Hauke8, Gerald Miletello9, Ulka Vaishampayan10, Douglas Johnson3, Richard White5, Peter Wiernik11, Janice Dutcher12

1Loyola University, Maywood, IL, USA 2Providence Cancer Center, Portland, OR, USA 3Vanderbilt University, Nashville, TN, USA 4Rutgers University, New Brunswick, NJ, USA 5Carolinas Health Care System, Charlotte, NC, USA 6University of Michigan, Ann Arbor, MI, USA 7University of Indiana, Indianapolis, IN, USA 8Midwest Cancer Center, Omaha, NE, USA 9Hematology/Oncology Clinic, LLP, Baton Rouge, LA, USA 10Wayne State University, Detroit, MI, USA 11Cancer Research Foundation of New York, Chappaqua, NY, USA 12Cancer Research Foundation of New York, Bronx, NY, USA

Clinical study | Cytokine | Clinical trial | Solid tumors

P320

Targeting CD38 beyond haematological malignancies: a panel of anti-CD38 antibodies with unique functional properties.

Nina Eissler1, Pascal Merchiers1, Simone Filosto1, Rahul Chaitanya Khanolkar1, Beatriz Goyenechea1, Dominic Smethurst1, Kevin Moulder1, Sergio A. Quezada2, Anne Goubier1

1Tusk Therapeutics, Stevenage, United Kingdom 2UCL Cancer Institute, London, United Kingdom

Costimulation | MDSC | T cell lineages | Antibody | Targeted therapy | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Regulatory T cell (Treg) | NK/NK T cell

P321

Ibrutinib in combination with agonist αOX40 mAb and CTLA-4 blockade induces Eomes hi CD8 T cells and promotes tumor regression

Dana Emerson1, Michael Mcnamara2, Ian Hilgart-Martiszus2, Mohammad Farhad2, William Redmond2

1Oregon Health & Science University, Portland, OR, USA 2Earle A. Chiles Research Institute, Portland, OR, USA

Costimulation | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Cytokine | Targeted therapy

P322

Antitumor Effects of Radiation Combined with Intratumoral Anti-Tem8 mAb and IL2

Amy K. Erbe1, Kathryn Komro1, Arika Feils1, Mackenzie Heck1, Sabrina VandenHeuvel1, Manasi Mohan1, Peter M. Carlson1, Jacquelyn A. Hank1, Alexander Rakhmilevich1, Zachary S. Morris1, Amit Chaudhary2, Brad St. Croix3, Paul M. Sondel1

1University of Wisconsin-Madison, Madison, WI, USA 2Meso Scale Diagnostics, Rockville, MD, USA 3National Cancer Institute, Frederick, MD, USA

Cytokine | NK/NK T cell | Radiotherapy | Tumor antigens | Targeted therapy | Tumor microenvironment | Costimulation | Antibody | Angiogenesis | Antigen presenting cells

P323

Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies

Heather Torrey1, Audrey Defusco1, Danielle Baum1, Ziba Rahbar2, Michael Khodadoust2, Youn H. Kim2, Denise Faustman1

1Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA 2Stanford University School of Medicine/Cancer Institute, Stanford, CA, USA

Immune tolerance | Regulatory T cell (Treg) | Tumor microenvironment | Antibody | T cell | Targeted therapy | Leukemia/Lymphoma

P324

Co-targeting of mesothelin and CD47 with bispecific antibodies for efficient elimination of solid tumors

Krzysztof Masternak1, Limin Shang1, Vanessa Buatois1, Stefano Majocchi1, Eric Hatterer1, Xavier Chauchet1, Valéry Moine1, Lucile Broyer1, Marie H. Kosco-Vilbois1, Nicolas Fischer1, Walter G. Ferlin1

1Novimmune S.A., Geneva, Switzerland

Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Solid tumors | Monocyte/Macrophage

P325

Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates

Randi Gombos1, Ana Gonzalez1, Mariana Manrique1, Dhan Chand1, David Savitsky1, Benjamin Morin1, Ekaterina Breous-Nystrom2, Christopher Dupont1, Rebecca Ward1, Cornelia Mundt3, Benjamin Duckless4, Hao Tang4, Mark Findeis1, Andrea Schuster3, Jeremy Waight1, Dennis Underwood1, Christopher Clarke1, Gerd Ritter5, Taha Merghoub6, David Schaer6, Marc van Dijk2, Jennifer Buell1, Jean-Marie Cuillerot1, Robert Stein1, Elise Drouin1, Nicholas WIlson1

1Agenus Inc., Lexington, MA, USA 2Agenus Switzerland Inc., Basel, Switzerland 3Former employee of Agenus Switzerland, Inc., Basel, Switzerland 4Former employee of Agenus Inc., Lexington, MA, USA 5Ludwig Institute for Cancer Research, New York, NY, USA 6Memorial Sloan Kettering Cancer Center, New York, NY, USA

Antibody | T cell | Cytokine | Immune toxicity | Immune monitoring | Checkpoint blockade

P326

Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy

Aditi Gupta1, Sadna Budhu1, Rachel Giese1, Jacques van Snick2, Catherine Uyttenhove2, Gerd Ritter3, Jedd Wolchok1, Taha Merghoub1

1Memorial Sloan Kettering, New York, NY, USA 2Ludwig Institute for Cancer Research Ltd Brussels Branch, Brussels, Belgium 3Ludwig Institute for Cancer Research, Ltd, New York, NY, USA

Tumor microenvironment | Targeted therapy | Solid tumors | Cytokine | Antibody | Immune suppression

P327

Intratumor injection of tumor-specific antibody and IL2 triggers in situ vaccination following local radiation therapy

Emily I. Guy1, Sara Busche1, Peter Carlson1, Clinton Heinze1, Ciara N. Schwarz1, Raghava N. Srirameneni1, Jasdeep Kler1, Michael M. Meagher2, Amy K. Erbe1, Jacquelyn A. Hank1, Alexander L. Rakhmilevich1, Paul M. Sondel1, Zachary S. Morris1

1University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 2St. Jude Children's Research Hospital/Children's GMP, LLC, Memphis, TN, Memphis, TN, USA

Antibody | Cytokine | Targeted therapy | Vaccine | Radiotherapy | T cell

P328

Therapeutic application of radiation-induced anti-tumor antibody

Tsuguhide Takeshima1, Raquibul Hannan1

1UT Southwestern Medical Center, Dallas, TX, USA

Dendritic cell | Radiotherapy | Antibody

P329

Dual blockade of PD1 and CTLA4 with bispecific antibody XmAb20717 promotes human T cell activation and proliferation

Michael Hedvat1, Matthew Bernett1, Gregory Moore1, Christine Bonzon1, Rumana Rashid1, Seung Chu1, Kendra Avery1, Alex Nisthal1, Umesh Muchhal1, John Desjarlais1

1Monrovia, CA, USA

Checkpoint blockade | Coinhibition | Targeted therapy | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Antibody

P330

T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects

Daniel Hirschhorn1, Jacob Ricca1, Bilel Gasmi1, Levi Mark Mangarin1, Olivier De Henau1, Sadna Budhu1, Yanyun Li1, Czrina Cortez1, Yang Xia1, Hong Zhong1, Cailian Liu1, Roberta Zappasodi1, Travis Hollmann1, Mario Lacouture1, Jean Albrengues2, Mikala Egeblad2, Wolchok Jedd1, Taha Merghoub1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Immune adjuvant | Solid tumors | Immune toxicity | Tumor stroma | Tumor microenvironment

P331

Involvement of estrogen and progesterone in the modulation of indoleamine 2,3 dioxygenase - IDO – expression in cultured mammary carcinoma cells of female dog

Jose Roberto Kfoury Jr.1, Pedro Bianchi1, Flavia Ponce1, Rafael Leandro1, Tulio Yoshinaga1

1School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil

Immune tolerance | Tumor microenvironment | Immune suppression | Tumor evasion

P332

Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology

Peter Kirk1, Peiwen Kuo1, Murali Addepalli1, Takahiro Miyazaki1, Jane Gunther1, Laurie VanderVeen1, Ping Zhang1, Palakshi Obalapur1, Mekhala Maiti1, Amol Murkar1, Arunasree Lanka1, Werner Rubas1, Jonathan Zalevsky1

1Nektar Therapeutics, San Francisco, CA, USA

Dendritic cell | T cell lineages | Cytokine | NK/NK T cell | T cell

P333

MPL-5821, an ESM™-p38 MAPK Inhibitor, Enhances Tumor Immune Response and M1 Macrophage Polarization in a 3D Ex Vivo System Utilizing Fresh Tumor Microspheroids of Lung Cancer Patients

Melanie Mediavilla-Varela1, Melba Marie Page1, Jenny Kreahling1, Martin Perry2, David Moffat2, Scott Antonia1, Soner Altiok1

1Nilogen Oncosystems, Tampa, FL, USA 2Macrophage Pharma Limited, Windsor, United Kingdom

Myeloid cells | Monocyte/Macrophage | Tumor microenvironment | Targeted therapy | Cytokine | Gene expression | Tumor infiltrating lymphocytes (TILs) | Tumor evasion | Immune monitoring

P334

Inhibition of IDO activity by epacadostat (INCB024360) activates tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer and alleviates stromal immunosuppression

Melanie Mediavilla-Varela1, Melba Marie Page1, Jenny Kreahling1, Peggy Scherle2, Scott Antonia1, Soner Altiok1

1Nilogen Oncosystems, Tampa, FL, USA 2Incyte Corporation, Wilmington, DE, USA

Cytokine | Chemokine | Targeted therapy | Solid tumors | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Gene expression | Tumor stroma | Immune suppression | Tumor evasion

P335

Characterization of a novel differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in vivo

Maaike Hendriks1, Joost Kreijtz1, Paul Vink1, David Lutje Hulsik1, Imke Lodewijks1, Astrid Bertens1, Jos van de Crommert1, Maurice Habraken1, Wout Janssen1, Judith Stammen-Vogelzang1, Weiwen Deng2, Laura Hix Glickman2, Meredith Leong2, Sarah McWhirter2, Thomas Dubensky2, Hans van Eenennaam1, Andrea van Elsas1

1Aduro Biotech Europe, Oss, Netherlands 2Aduro Biotech, Inc., Berkeley, CA, USA

Antibody | T cell | Regulatory T cell (Treg) | Checkpoint blockade

P336

Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody

Ross La Motte-Mohs1, Kalpana Shah1, Jennifer G. Brown1, Ralph F. Alderson1, Doug Smith2, Sergey Gorlatov1, Valentina Ciccarone1, James K. Tamura1, Hua Li1, Leilei He1, Farha Vasanwala1, Jill R. Rillema2, Monica Licea2, Jessica Hill1, Christina Wolff1, Massimiliano Pascuccio1, Francine Z. Chen2, Yan Chen2, Anushka De Costa2, Ann Easton2, Alexey Berezhnoy1, Jonathan Li2, Jeffrey Nordstrom1, Scott Koenig1, Ezio Bonvini1, Syd Johnson1, Paul A. Moore1

1MacroGenics, Inc., Rockville, MD, USA 2MacroGenics, Inc., South San Francisco, CA, USA

Checkpoint blockade | Targeted therapy | T cell | Coinhibition

P337

Preclinical characterization of MGD013, a PD-1 x LAG-3 bispecific DART® molecule

Ross La Motte-Mohs1, Kalpana Shah1, Jennifer G. Brown1, Doug Smith2, Sergey Gorlatov1, Valentina Ciccarone3, James K. Tamura1, Hua Li1, Leilei He1, Farha Vasanwala1, Christine Shoemaker1, Jonathan Li2, Shereen Saini2, Jill R Rillema2, Monica Licea2, Jessica Hill1, Arin Whiddon1, Massimiliano Pascuccio1, Francine Z. Chen2, Anushka De Costa2, Ann Easton2, Peter Lung2, Kurt Stahl1, Jeffrey Nordstrom1, Scott Koenig1, Ezio Bonvini1, Syd Johnson1, Paul A. Moore1

1MacroGenics, Inc., Rockville, MD, USA 2MacroGenics, Inc., South San Francisco, CA, USA 3MacroGenics, Inc., Rockville, CA, USA

Checkpoint blockade | T cell | Targeted therapy | Coinhibition

P338

Combined IL-6 and CTLA4 blockade enhances CD8+ T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models.

Christopher McQuinn1, Matthew Farren2, Thomas Mace1, Jacob Bowers3, Reena Shakya1, A. Brad Ferris2, Gregory Young1, William Carson, III1, Chrystal Paulos3, Bassel El-Rayes2, Gregory Lesinski2

1The Ohio State University, Columbus, OH, USA 2Winship Cancer Institute of Emory University, Atlanta, GA, USA 3Medical University of South Carolina, Charleston, SC, USA

Immune suppression | Checkpoint blockade | Antibody | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Tumor stroma | Cytokine | Tumor microenvironment | Chemokine

P339

Critical Role of Hematopoietic Progenitor Kinase 1 in Anti-tumor Immune Responses

Dan You1, Stephen Hillerman1, Jesse Swanson1, Ching-Ping Ho1, Anwar Murtaza1, Rukiye Eraslan1, Miguel Sanjuan1, John Hunt1, Luisa Salter-Cid1, Joshua Curtin2, Jinqi Liu1

1Bristol-Myers Squibb, Lawrence Township, NJ, USA 2Johnson & Johnson Pharmaceutical, Spring House, PA, USA

Cytokine | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Inflammation

P340

In vitro effects and mechanism of hu14.18-IL2 immunocytokine against GD2 positive pediatric malignancies.

Holger Lode1, Maxi Zumpe1, Madlen Juettner1, Sascha Troschke-Meurer1, Evelyne Janzek2, Romana Schaefer2, Bettina Neuchrist2, Nikolai Siebert1, Hans Loibner2

1University Medicine Greifswald, Greifswald, Germany 2Apeiron Biologics, Vienna, Austria

Checkpoint blockade | Antibody | Pediatric tumors

P341

Peripheral Immunomodulatory Changes in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated with Nivolumab

Lorena Almeida1, Manuel Maia1, Haejung Won1, Dayson Moreira1, Paulo Bergerot1, Marcin Kortylewski1, Sumanta Pal1

1City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Biomarkers | Cytokine | Checkpoint blockade | T cell | Chemokine | Immune monitoring

P342

Blood in circulation, with intact cascade systems, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Erika Fletcher1, Mohamed Elthahir1, Frida Lindqvist2, Jonas Rieth1, Gunilla Törnqvist2, Justyna Leja-Jarblad1,2, Sara Mangsbo1,2

1Uppsala University, Uppsala, Sweden 2Immuneed AB, Uppsala, Sweden

Antibody | Chemokine | Immune monitoring | Immune toxicity | Cytokine

P343

Novel Immuno-Oncology Biologics Derived via Directed Evolution of IgSF Domains

Mark Maurer1, Ryan Swanson1, Michael Kornacker1, Steve Levin1, Chris Navas1, Chelsea Gudgeon1, Lawrence Evans1, Martin Wolfson1, Dan Ardourel1, Daniel DeMonte1, Joseph Kuijper1, Sean MacNeil1, Janhavi Bhandari1, Mark Rixon1, Stanford Peng1

1Alpine Immune Sciences, Inc., Seattle, WA, USA

Costimulation | Tumor microenvironment | Checkpoint blockade | Coinhibition | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Immune suppression

P344

Development and functional characterization of COM902, a novel therapeutic antibody targeting the immune checkpoint TIGIT

Sandeep Kumar1, Radhika Desai1, Hsin-Yuan Cheng1, Kyle Hansen1, Andy Drake1, Patrick Wall1, Kathryn Logronio1, Gady Cojocaru2, John Hunter1, Mark White1, Spencer Liang1, Maya Kotturi1

1Compugen USA, Inc., South San Francisco, CA, USA 2Compugen Ltd., Holon, Israel

Regulatory T cell (Treg) | Checkpoint blockade | Coinhibition | Targeted therapy | Antibody | NK/NK T cell | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors

P345

Tumor protective effect of anti-MUC1.IgE in pancreatic cancer

Kamiya Mehla1, James A Grunkemeyer1, Ragupathy Madiyalakan2, Christopher F Nicodemus3, Michael A Hollingsworth1

1University of Nebraska Medical Centre, Omaha, NE, USA 2Oncoquest, Edmonton,, AB, Canada 3AIT Strategies, Franconia, NH, USA

Dendritic cell | Inflammation | Immune adjuvant | Tumor antigens | Solid tumors | T cell | TLR | Targeted therapy | Antibody | Checkpoint blockade

P346

Inhibition of MMP9 Yields Improved Effector T cell Responses in a PD1-Axis Refractory Model

Amanda Mikels-Vigdal1, Vladi Juric1, Chris O'Sullivan1, Erin Stefanutti1, Andrew Greenstein1, Maria Kovalenko1, Jeremiah Degenhardt1, Peng Yue1, Victoria Smith1

1Gilead Sciences, Inc, Foster City, CA, USA

Myeloid cells | Tumor microenvironment | Tumor stroma | Antibody | T cell | Monocyte/Macrophage | Immune suppression | Checkpoint blockade

P347

Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation

Gregory Moore1, Michael Hedvat1, Matthew Bernett1, Christine Bonzon1, Rajat Varma1, Suzanne Schubbert1, Sung-Hyung Lee1, Kendra Avery1, Rumana Rashid1, Alex Nisthal1, Liz Bogaert1, Irene Leung1, Seung Chu1, Umesh Muchhal1, John Desjarlais1

1Xencor, Inc., Monrovia, CA, USA

Antibody | Checkpoint blockade | Costimulation | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P348

Dual Blockade of PD-L1 and LAG-3 with FS118, a Unique Bispecific Antibody, Induces T-cell Activation with the Potential to Drive Potent Anti-tumour Immune Responses

Matthew Kraman1, Natalie Fosh1, Katarzyna Kmiecik1, Katy Everett1, Carlo Zimarino1, Mustapha Faroudi1, Mateusz Wydro1, Alexander Koers1, Lesley Young1, Michelle Morrow1, Jacqueline Doody1, Mihriban Tuna1, Neil Brewis1

1F-star, Cambridge, United Kingdom

Immune tolerance | Regulatory T cell (Treg) | Checkpoint blockade | Coinhibition | Antibody | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs)

P349

Molecular-targeted radiotherapy with an alkyl-phosphocholine analog leads toimmunomodulation in a syngeneic murine melanoma model

Suresh Veerankutty1, Peter Carlson1, Dana Baiu1, Clinton Heinze1, Alexander Boruch1, Amy Erbe1, Joseph Grudzinski1, Reinier Hernandez1, Bryan Bednarz1, Jamey Weichert1, Paul Sondel1, Zachary Morris1, Mario Otto1

1University of Wisconsin, Madison, WI, USA

Tumor microenvironment | Targeted therapy | Radiotherapy | Tumor infiltrating lymphocytes (TILs)

P350

Breast tumor suppression mediated by therapeutic expression of chemerin, an innate leukocyte chemoattractant

Russell Pachynski1, Ping Wang1, Brian Zabel2, Eugene Butcher2

1Washington University School of Medicine, St Louis, MO, USA 2Stanford University, Palo Alto, CA, USA

Chemokine | NK/NK T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Targeted therapy | Immune adjuvant

P351

A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230

Lukas Pfannenstiel1, Jared Lopes2, Heather Losey2, Juan Alvarez2, Brian Gastman1

1Cleveland Clinic, Cleveland, OH, USA 2Alkermes, Inc., Waltham, MA, USA

Adoptive immunotherapy | Tumor antigens | Cytokine | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P352

A novel CD73 blocking antibody restores T cell function and augments efficacy of Adenosine 2A Receptor (A2AR) inhibitor CPI-444

Emily Piccione1, Jenny Rudnick1, Barbara Daine-Matsuoka1, Glen Mikesell1, Richard Miller1, Ian McCaffery1

1Corvus Pharmaceuticals, Burlingame, CA, USA

Tumor microenvironment | Antibody | Immune suppression

P353

Discovery and pre-clinical development of an orally available small molecule antagonist targeting the CD47/SIRPα pathway for cancer immunotherapy

Pottayil Sasikumar1, Chennakrishna Gundala1, Wesley Balasubramanian1, Sudarshan Naremaddepalli1, Archana Bhumireddy1, Sandeep Patil1, Amit Dhudashiya1, Vijaysai Rayavarapu1, Anirudha Lakshminarasimhan1, Samiulla Dodheri1, Kiran Aithal1, Girish Daginakatte1, Murali Ramachandra1

1Aurigene Discovery Technologies Limited, Bangalore, India

Tumor microenvironment | Monocyte/Macrophage | Cytokine | Tumor evasion

P354

An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activity

Pottayil Sasikumar1, Sudarshan Naremaddepalli1, Raghuveer Ramachandra1, Nagesh Gowda1, Govardhan Alluri1, Manikyalarao Yerramsetti1, Sreenivas Adurthi1, Jiju Mani1, Rashmi Nair1, Amit Dhudashiya1, Samiulla- Dodheri1, Nagaraj Gowda1, Murali Ramachandra1

1Aurigene Discovery Technologies Limited, Bangalore, India

Tumor microenvironment | MDSC | Checkpoint blockade | Coinhibition | Tumor evasion

P355

Epigenetic modulation promotes tumor suppression and improves survival when combined with checkpoint inhibition in murine models of breast cancer

Evanthia Roussos Torres1, Hayley Ma1, Christine Rafie1, Brian Christmas1, Todd Armstrong1, Elizabeth Jaffee1

1Johns Hopkins University, Baltimore, MD, USA

Inflammation | Myeloid cells | Tumor microenvironment | Checkpoint blockade | Gene expression | Immune suppression | MDSC | Tumor infiltrating lymphocytes (TILs) | Clinical study | Monocyte/Macrophage

P356

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16-OVA Melanoma Model

Ruchi Saxena1, Yan Wang2, James Mier1

1Beth Israel Deaconess Medical Center, Boston, MA, USA 2X4 Pharmaceuticals, Cambridge, MA, USA

Regulatory T cell (Treg) | Tumor microenvironment | Chemokine | Tumor infiltrating lymphocytes (TILs)

P357

The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance

Ian Frank1, Michelle Simpson-Abelson1, Michael Lotze1, Krit Ritthipichai1, Christopher Mosychuk1

1Iovance Biotherapeutics, Tampa Bay, FL, USA

Adoptive immunotherapy | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Cytokine | Tumor microenvironment | Clinical trial

P358

Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy

Lawrence Thomas1, Laura Vitale2, Thomas O'Neill2, Jenifer Widger2, Andrea Crocker2, Li-Zhen He2, Jeffrey Weidlick2, Karuna Sundarapandiyan2, James Storey1, Eric Forsberg1, Catherine Pilsmaker1, Lauren Gergel1, Elizabeth Do1, Joel Goldstein2, Henry Marsh1, Tibor Keler2

1Celldex Therapeutics, Needham, MA, USA 2Celldex Therapeutics, Hampton, NJ, USA

Antigen presenting cells | Dendritic cell | Immune contexture | Regulatory T cell (Treg) | MDSC | Antibody | B cell | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs)

P359

Effect of targeted anti-GD2/-CD16 Bispecific NK cell Engager (BiKE) with or without IL-15 super agonist ALT803 against GD2+ Neuroblastoma (NB) and Ewing Sarcoma (ES)

Aradhana Tiwari1, Dina Edani1, Janet Ayello1, Hing C. Wong2, Mitchell S Cairo1

1New York Medical College, Valhalla, NY, USA 2Altor BioscienceWebsiteDirections, Miramar, FL, USA

Antibody | Adoptive immunotherapy | Pediatric tumors | Tumor microenvironment | Targeted therapy | Tumor antigens | B cell | NK/NK T cell

P360

APX005M is a potent CD40 agonistic antibody capable of stimulating both innate and adaptive immune responses against cancer

Pia Björck1, Erin Filbert1, Ovid Trifan1, Xiaodong Yang1

1Apexigen Inc., San Carlos, CA, USA

Antigen presenting cells | Dendritic cell | Antibody | Monocyte/Macrophage | B cell | Cytokine | T cell

P361

A Novel T-Cell Engaging Bispecific Antibody Platform: Efficient In vivo Tumor Clearance with Minimal Cytokine Release

Nathan Trinklein1, Andrew Boudreau1, Ben Buelow1, Starlynn Clarke1, Kevin Dang1, Laura Davison1, Shelley Force Aldred1, Katherine Harris1, Suhasini Iyer1, Brett Jorgensen1, Heather Ogana1, Duy Pham1, Payal Pratap1, Udaya Rangaswamy1, Ute Schellenberger1, Harshad Ugamraj1, Omid Vafa1, Wim van Schooten1

1Teneobio, Menlo Park, CA, USA

Bioinformatics | Immune toxicity | Leukemia/Lymphoma | Tumor antigens | T cell | Antibody

P362

A novel assay using RNA aptamers to quantitate the fraction of IL2Ra (CD25) receptors occupied by IL2

Suresh Veeramani1, Sue Blackwell1, William Thiel1, Paloma Giangrande1, George Weiner1

1University of Iowa, Iowa City, IA, USA

Regulatory T cell (Treg) | Tumor microenvironment | Immune monitoring | Cytokine

P363

The OX40-CTLA-4 bispecific antibody, ATOR-1015, induces immune activation and anti-tumor effect

Niina Veitonmäki1, Karin Hägerbrand1, Mia Thagesson1, Doreen Werchau1, Karin Enell-Smith1, Anna Rosén1, Sara Frizell1, Anne Månsson-Kvarhammar1, Per Norlén1, Furebring Tina1, Peter Ellmark1

1Alligator Bioscience, Lund, Sweden

Antibody | Checkpoint blockade | Regulatory T cell (Treg) | T cell | Tumor infiltrating lymphocytes (TILs)

P364

Discovery and pharmacological characterization of JNJ-63723283, an anti-programmed cell death protein-1 (PD-1) antibody that blocks PD-1 function

Catherine Ferrante1, Nikki DeAngelis1, Gordon Powers1, Jocelyn Sendecki1, Hillary Millar2, Bethany Mattson1, Darlene Pizutti1, Christina Lourdes Mayer1, Weirong Wang1, Raymond Brittingham1, John Wheeler1, Linda Barone1, Rupesh Nanjunda1, Eilyn R. Lacy1, Sheng-Jiun Wu1, Jinquan Luo3, Enrique Zudaire1, Kathryn Packman1, Brian Geist1, Kevin Trouba1, Matthew V. Lorenzi1, Raluca I. Verona1

1Janssen Research & Development, Spring House, PA, USA 2Janssen Research & Development, Beerse, Belgium 3Janssen Resaerch & Development, Spring House, PA, USA

Tumor microenvironment | Antibody | Checkpoint blockade | T cell | Solid tumors | NK/NK T cell

P365

Development of JNJ-64158120, an anti-TIM-3 antibody to overcome innate and acquired mechanisms of resistance to PD-1 therapy

Nikki DeAngelis1, Gordon Powers1, Keri Dorn1, Matthew Chomo1, Douglas Dolfi1, Karla Wiehagen1, Douglas Marvel1, Bethany Mattson1, Darlene Pizutti1, Liam Campion1, Caitlin Morgan1, Brian Tomkowicz1, Nina Sabins1, Sandra Santulli-Marotto2, Jocelyn Sendecki1, John Wheeler1, Brian Whitaker1, Annmarie Winkis1, Linda Barone1, Deborah Kwok1, Eilyn R. Lacy1, Edmund Moon3, Steve Albelda3, Kathryn Packman1, Enrique Zudaire1, Matthew V. Lorenzi1, Raluca I. Verona1

1Janssen Research & Development, Spring House, PA, USA 2Alios BioPharma/Janssen Research & Development, South San Francisco, PA, USA 3University of Pennsylvania, Philadelphia, PA, USA

Antibody | Checkpoint blockade | NK/NK T cell | Solid tumors | T cell | Tumor microenvironment

P366

Anti–PD-L1 mAb treatment combined with cisplatin modulates intratumoral immune responses and promotes antitumor effects

Daiko Wakita1, Toshiki Iwai1, Masamichi Sugimoto1, Suguru Harada1, Miho Suzuki1, Kaname Yamamoto1

1Chugai pharmaceutical CO., LTD., Kamakura, Japan

Chemotherapy | Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs)

P367

X4P-001, an orally bioavailable CXCR4 antagonist, increases T cell infiltration in human metastatic melanoma

Robert Andtbacka1, Melinda Yushak2, Merrick Ross3, Kenneth Grossman1, Eleni Tsiroyanni4, Sarah Blanchette4, Lu Gan4, Yan Wang4, Mohammed Milhem5

1Huntsman Cancer Institute, Salt Lake City, UT, USA 2Winship Cancer Institute, Atlanta, GA, USA 3MD Anderson Cancer Center, Houston, TX, USA 4X4 Pharmaceuticals, Cambridge, MA, USA 5University of Iowa, Iowa City, IA, USA

Tumor microenvironment | Clinical study | Clinical trial | T cell

P368

eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response

Kevin Webster1, Rajesh Sharma1, Vikas Goel1, Craig Stumpf1, Jocelyn Stauton1, Peggy Thompson1, Gary Chiang1, Yichen Xu2, Hyun Yong Jin2, Davide Ruggero2

1eFFECTOR Therapeutics, San Diego, CA, USA 2Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Tumor microenvironment | Cytokine | Adoptive immunotherapy | T cell lineages | Dendritic cell | Targeted therapy | Checkpoint blockade | Clinical trial | T cell | Tumor infiltrating lymphocytes (TILs)

P369

Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902

Sarah Whelan1, Ling Leung1, David Bernardos1, John Hunter1, Mark White1, Spencer Liang1

1Compugen USA, Inc., South San Francisco, CA, USA

Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Antibody | Checkpoint blockade | Targeted therapy | T cell | NK/NK T cell

P370

Enhancement of tumor specific immunity by activation of CD40 through a bispecific molecule targeting CD40 and a tumor surface antigen

Shiming Ye1, Diane Yu1, Nicole Belmar1, Donghee Choi1, Debra Chao1, Mien Sho1, Han Kim1, Jean Cabel2, Danying Song2, Kelley Hiser2, John Harlan2, Catherine Zhang1, Yuni Fang1, Steve Keller1, Alan Wahl3, Patricia Culp4, Diane Hollenbaugh1

1AbbVie Biotherapeutics Inc., Redwood City, CA, USA 2AbbVie Inc., North Chicago, IL, USA 3Former AbbVie Employee, Del Mar, CA, USA 4Former AbbVie Employee (currently working at Alector Inc.), South San Francisco, CA, USA

Antibody | Antigen presenting cells | Costimulation | Solid tumors | Targeted therapy | Tumor antigens | T cell | Immune contexture | Immune toxicity